Fostemsavir: First Approval

<p><b>Declarations</b></p><p><b><i>Funding</i></b> The preparation of this review was not supported by any external funding.</p><p><br></p><p><b><i>Authorship and Conflict of interest</i></b> A. Markham is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</p><p></p><p></p><p></p><p><b><i>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability </i></b>not applicable<b></b></p><p><br></p><p>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a></b><br></p><p><br></p><p><b>Abstract</b></p><p><br></p><p></p><p>Fostemsavir (Rukobia), a prodrug of the HIV-1 attachment inhibitor temsavir, is a first-in-class treatment for HIV infection being developed by ViiV Healthcare. Based on the results of the phase III BRIGHTE trial fostemsavir was recently approved in the USA for the treatment of patients with HIV not able to be treated with other therapies. This article summarizes the milestones in the development of fostemsavir leading to this first approval.</p><p><br></p><p>© Springer Nature Switzerland AG 2020</p>